Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.49 |
| ▸ | UGT2B7 | P16662 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1988215 | 1.00 | CNR1 (0.49) | CNR1UGT2B7MEN1KMT2ACYP1A2 | |
| SCHEMBL6298892 | 0.80 | ALDH1A1 (0.56) | CNR1UGT2B7MEN1KMT2ACYP1A2 | |
| SCHEMBL6300038 | 0.80 | ALDH1A1 (0.56) | CNR1UGT2B7MEN1KMT2ACYP1A2 | |
| SCHEMBL1985442 | 0.78 | NPC1 (0.51) | CNR1MEN1KMT2AAOC3 | |
| SCHEMBL27862778 | 0.78 | NPC1 (0.51) | CNR1MEN1KMT2AAOC3 | |
| SCHEMBL3486501 | 0.78 | NPC1 (0.51) | CNR1MEN1KMT2AAOC3 | |
| SCHEMBL6678168 | 0.77 | UGT2B7 (0.57) | UGT2B7MEN1KMT2ACYP1A2CYP2D6 | |
| SCHEMBL1319593 | 0.75 | CNR1 (0.43) | CNR1UGT2B7MEN1KMT2ACYP1A2 | |
| SCHEMBL5401290 | 0.74 | UGT2B7 (0.59) | UGT2B7MEN1KMT2ACYP1A2CYP2D6 | |
| SCHEMBL16684715 | 0.74 | UGT2B7 (0.59) | UGT2B7MEN1KMT2ACYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9744528-B2 | Metallorganocatalysis for asymmetric transformations | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2017-08-29 | — | — | US | disclosed |
| US-9744528-B2 | Metallorganocatalysis for asymmetric transformations | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2017-08-29 | — | — | US | disclosed |
| US-20160023198-A1 | Metallorganocatalysis For Asymmetric Transformations | Rutgars, The State University of New Jersey (US) | 2016-01-28 | — | — | US | disclosed |
| US-20160023198-A1 | Metallorganocatalysis For Asymmetric Transformations | Rutgars, The State University of New Jersey (US) | 2016-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160023198-A1 | Metallorganocatalysis For Asymmetric Transformations | SOD1, AOC3, CBR1 | CNR1 739/4885UGT2B7 3924/4885MEN1 3293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.